Polycythemia risk factors: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
|||
| (12 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycythemia}} | {{Polycythemia}} | ||
{{CMG}} {{AE}} | {{CMG}} ; {{AE}} {{Debduti}} | ||
==Overview== | ==Overview== | ||
There are no established | There are no established [[Risk factor|risk factors]] for developing [[polycythemia vera]] except for the genetic abnormality [[JAK2]]V617F. | ||
==Risk Factors== | ==Risk Factors== | ||
*One of the most common and most dangerous [[complications]] of [[polycythemia vera]] is [[thrombus]] formation. The risk factors are as follows:<ref name="BarbuiCarobbio2014">{{cite journal|last1=Barbui|first1=Tiziano|last2=Carobbio|first2=Alessandra|last3=Rumi|first3=Elisa|last4=Finazzi|first4=Guido|last5=Gisslinger|first5=Heinz|last6=Rodeghiero|first6=Francesco|last7=Randi|first7=Maria Luigia|last8=Rambaldi|first8=Alessandro|last9=Gisslinger|first9=Bettina|last10=Pieri|first10=Lisa|last11=Bertozzi|first11=Irene|last12=Casetti|first12=Ilaria|last13=Pardanani|first13=Animesh|last14=Passamonti|first14=Francesco|last15=Vannucchi|first15=Alessandro M.|last16=Tefferi|first16=Ayalew|title=In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology|journal=Blood|volume=124|issue=19|year=2014|pages=3021–3023|issn=0006-4971|doi=10.1182/blood-2014-07-591610}}</ref><ref>{{cite journal|doi=10.36648/1791-809X.14.6.763}}</ref><ref name="pmid9387204">{{cite journal| author=Barbui T, Finazzi G| title=Risk factors and prevention of vascular complications in polycythemia vera. | journal=Semin Thromb Hemost | year= 1997 | volume= 23 | issue= 5 | pages= 455-61 | pmid=9387204 | doi=10.1055/s-2007-996122 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9387204 }}</ref><ref name="pmid28251679">{{cite journal| author=Abdulkarim K, Samuelsson J, Johansson P, Andréasson B| title=Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry. | journal=Eur J Haematol | year= 2017 | volume= 98 | issue= 6 | pages= 577-583 | pmid=28251679 | doi=10.1111/ejh.12873 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28251679 }}</ref> | |||
*Women- usually younger at the time of [[diagnosis]], have a higher risk of arterio-venous [[thrombosis]]. | |||
*[[Mutation]]- the higher burden of JAK2V617F [[allele]] | |||
*[[Inflammatory]] markers- [[Pentraxins]] play an important role: increased hs-[[CRP]] and a lower [[PTX3]] have a higher risk of [[thrombosis]]. | |||
*Presence of microparticles- responsible for decreased [[thrombin]] inhibition, increased CD41, and an increased chance of [[splenomegaly]]. | |||
*[[Neutrophil]] Extracellular Trap formations- NETosis and [[apoptosis]]. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WS}} | {{WS}} | ||
{{WH}} | {{WH}} | ||
[[Category:Hematology]] | |||
[[Category:Emergency medicine]] | |||
[[Category:Disease]] | |||
[[Category:Blood disorders]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 17:19, 2 March 2021
|
Polycythemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Polycythemia risk factors On the Web |
|
American Roentgen Ray Society Images of Polycythemia risk factors |
|
Risk calculators and risk factors for Polycythemia risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Debduti Mukhopadhyay, M.B.B.S[2]
Overview
There are no established risk factors for developing polycythemia vera except for the genetic abnormality JAK2V617F.
Risk Factors
- One of the most common and most dangerous complications of polycythemia vera is thrombus formation. The risk factors are as follows:[1][2][3][4]
- Women- usually younger at the time of diagnosis, have a higher risk of arterio-venous thrombosis.
- Mutation- the higher burden of JAK2V617F allele
- Inflammatory markers- Pentraxins play an important role: increased hs-CRP and a lower PTX3 have a higher risk of thrombosis.
- Presence of microparticles- responsible for decreased thrombin inhibition, increased CD41, and an increased chance of splenomegaly.
- Neutrophil Extracellular Trap formations- NETosis and apoptosis.
References
- ↑ Barbui, Tiziano; Carobbio, Alessandra; Rumi, Elisa; Finazzi, Guido; Gisslinger, Heinz; Rodeghiero, Francesco; Randi, Maria Luigia; Rambaldi, Alessandro; Gisslinger, Bettina; Pieri, Lisa; Bertozzi, Irene; Casetti, Ilaria; Pardanani, Animesh; Passamonti, Francesco; Vannucchi, Alessandro M.; Tefferi, Ayalew (2014). "In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology". Blood. 124 (19): 3021–3023. doi:10.1182/blood-2014-07-591610. ISSN 0006-4971.
- ↑ . doi:10.36648/1791-809X.14.6.763. Missing or empty
|title=(help) - ↑ Barbui T, Finazzi G (1997). "Risk factors and prevention of vascular complications in polycythemia vera". Semin Thromb Hemost. 23 (5): 455–61. doi:10.1055/s-2007-996122. PMID 9387204.
- ↑ Abdulkarim K, Samuelsson J, Johansson P, Andréasson B (2017). "Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: Real-world data from the Swedish MPN Registry". Eur J Haematol. 98 (6): 577–583. doi:10.1111/ejh.12873. PMID 28251679.